The Resource Lung cancer and personalized medicine : novel therapies and clinical management, Aamir Ahmad, Shirish M. Gadgeel, editors

Lung cancer and personalized medicine : novel therapies and clinical management, Aamir Ahmad, Shirish M. Gadgeel, editors

Label
Lung cancer and personalized medicine : novel therapies and clinical management
Title
Lung cancer and personalized medicine
Title remainder
novel therapies and clinical management
Statement of responsibility
Aamir Ahmad, Shirish M. Gadgeel, editors
Contributor
Subject
Genre
Language
eng
Summary
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality
Member of
Cataloging source
IDEBK
Dewey number
  • 616.99/42406
  • 610
Index
index present
LC call number
RC280.L8
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
WF 658
http://library.link/vocab/relatedWorkOrContributorName
  • Ahmad, Aamir
  • Gadgeel, Shirish
Series statement
Advances in experimental medicine and biology,
Series volume
v. 890
http://library.link/vocab/subjectName
  • Lungs
  • HEALTH & FITNESS
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • Lungs
  • Biomedicine
  • Cancer Research
  • Lung Neoplasms
  • Oncology
Label
Lung cancer and personalized medicine : novel therapies and clinical management, Aamir Ahmad, Shirish M. Gadgeel, editors
Link
https://ezproxy.lib.ou.edu/login?url=http://link.springer.com/10.1007/978-3-319-24932-2
Instantiates
Publication
Note
Includes index
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Contributors; Preface; Contents; Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development; 1 Oncogenes, Tumor Suppressors and Targeted Therapeutics; 2 Somatic Copy Number Alterations and Coding Mutation Frequencies According to Lung Cancer Subtype; 2.1 Lung Adenocarcinoma; 2.1.1 EGFR; 2.1.2 KRAS; 2.1.3 BRAF; 2.1.4 HER2; 2.1.5 MET; 2.2 Squamous Cell Lung Cancer; 2.2.1 Somatic Copy Number Alterations in Squamous Cell Lung Cancer; 2.2.2 Somatic Coding Mutations in Squamous Cell Lung Cancer; 2.3 Small Cell Lung Cancer; 3 Genomic Translocations and Expressed Fusion Genes; 3.1 ALK
  • 3.2 ROS1; 3.3 RET; 4 Challenges and Conclusions; References; Emerging Biomarkers in Personalized Therapy of Lung Cancer; 1 Introduction; 2 ROS1; 3 RET; 4 MET; 5 HER 2; 6 BRAF; References; Epithelial Mesenchymal Transition in Aggressive Lung Cancers; 1 Epithelial Mesenchymal Transition in Cancer: Overview; 2 Epithelial Mesenchymal Transition in Physiological Processes and Cancer; 3 Epithelial Mesenchymal Transition in Primary Tumor and Metastatic Dissemination; 4 Epithelial Mesenchymal Transition in Lung Cancer; 4.1 Epithelial Mesenchymal Transition and Prognosis in Lung Cancer
  • 4.2 Epithelial Mesenchymal Transition and Lung Cancer Progression; 4.3 Epithelial Mesenchymal Transition and Drug Resistance in Lung Cancer; 5 Therapeutic Potential of Targeting Epithelial Mesenchymal Transition in Lung Cancer; 6 Future Perspectives; References; The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer; 1 Introduction; 2 Cancer Stem Cells of the Lungs; 2.1 Markers Defining Lung CSCs and Their Potential Biological Implications; 2.1.1 CD133; 2.1.2 ALDH; 2.1.3 ABCG2; 2.1.4 Nanog; 2.2 Therapeutic Targeting of Lung CSC Markers; 3 Drug-Resistance
  • 3.1 Role of EMT in Drug-Resistance; 3.2 Role of CSCs in Drug-Resistance; 4 The Role of miRNAs; 4.1 MicroRNAs Associated with Chemoresistance; 4.1.1 miR-212; 4.1.2 The let-7 Family; 4.1.3 miRNAs Associated with EGFR; 4.2 MicroRNAs Associated with CSCs; 4.2.1 miR-34a; 4.2.2 miR-21; 4.2.3 The miR-200 Family; 5 Natural Agents and Their Synthetic Derivative as Anti-cancer Compounds; 5.1 BR-DIM; 5.2 Curcumin; 5.3 CDF; 6 Conclusions: The Future of CSCs and CSC-Targeted Treatment; References; The Microenvironment of Lung Cancer and Therapeutic Implications; 1 The Tumor Microenvironment: An Overview
Dimensions
unknown
Extent
1 online resource.
Form of item
online
Isbn
9783319249322
Media category
computer
Media MARC source
rdamedia
Media type code
c
Note
SpringerLink
Other control number
10.1007/978-3-319-24932-2
Specific material designation
remote
System control number
  • (OCoLC)933587256
  • (OCoLC)ocn933587256
Label
Lung cancer and personalized medicine : novel therapies and clinical management, Aamir Ahmad, Shirish M. Gadgeel, editors
Link
https://ezproxy.lib.ou.edu/login?url=http://link.springer.com/10.1007/978-3-319-24932-2
Publication
Note
Includes index
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Contributors; Preface; Contents; Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development; 1 Oncogenes, Tumor Suppressors and Targeted Therapeutics; 2 Somatic Copy Number Alterations and Coding Mutation Frequencies According to Lung Cancer Subtype; 2.1 Lung Adenocarcinoma; 2.1.1 EGFR; 2.1.2 KRAS; 2.1.3 BRAF; 2.1.4 HER2; 2.1.5 MET; 2.2 Squamous Cell Lung Cancer; 2.2.1 Somatic Copy Number Alterations in Squamous Cell Lung Cancer; 2.2.2 Somatic Coding Mutations in Squamous Cell Lung Cancer; 2.3 Small Cell Lung Cancer; 3 Genomic Translocations and Expressed Fusion Genes; 3.1 ALK
  • 3.2 ROS1; 3.3 RET; 4 Challenges and Conclusions; References; Emerging Biomarkers in Personalized Therapy of Lung Cancer; 1 Introduction; 2 ROS1; 3 RET; 4 MET; 5 HER 2; 6 BRAF; References; Epithelial Mesenchymal Transition in Aggressive Lung Cancers; 1 Epithelial Mesenchymal Transition in Cancer: Overview; 2 Epithelial Mesenchymal Transition in Physiological Processes and Cancer; 3 Epithelial Mesenchymal Transition in Primary Tumor and Metastatic Dissemination; 4 Epithelial Mesenchymal Transition in Lung Cancer; 4.1 Epithelial Mesenchymal Transition and Prognosis in Lung Cancer
  • 4.2 Epithelial Mesenchymal Transition and Lung Cancer Progression; 4.3 Epithelial Mesenchymal Transition and Drug Resistance in Lung Cancer; 5 Therapeutic Potential of Targeting Epithelial Mesenchymal Transition in Lung Cancer; 6 Future Perspectives; References; The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer; 1 Introduction; 2 Cancer Stem Cells of the Lungs; 2.1 Markers Defining Lung CSCs and Their Potential Biological Implications; 2.1.1 CD133; 2.1.2 ALDH; 2.1.3 ABCG2; 2.1.4 Nanog; 2.2 Therapeutic Targeting of Lung CSC Markers; 3 Drug-Resistance
  • 3.1 Role of EMT in Drug-Resistance; 3.2 Role of CSCs in Drug-Resistance; 4 The Role of miRNAs; 4.1 MicroRNAs Associated with Chemoresistance; 4.1.1 miR-212; 4.1.2 The let-7 Family; 4.1.3 miRNAs Associated with EGFR; 4.2 MicroRNAs Associated with CSCs; 4.2.1 miR-34a; 4.2.2 miR-21; 4.2.3 The miR-200 Family; 5 Natural Agents and Their Synthetic Derivative as Anti-cancer Compounds; 5.1 BR-DIM; 5.2 Curcumin; 5.3 CDF; 6 Conclusions: The Future of CSCs and CSC-Targeted Treatment; References; The Microenvironment of Lung Cancer and Therapeutic Implications; 1 The Tumor Microenvironment: An Overview
Dimensions
unknown
Extent
1 online resource.
Form of item
online
Isbn
9783319249322
Media category
computer
Media MARC source
rdamedia
Media type code
c
Note
SpringerLink
Other control number
10.1007/978-3-319-24932-2
Specific material designation
remote
System control number
  • (OCoLC)933587256
  • (OCoLC)ocn933587256

Library Locations

  • Architecture LibraryBorrow it
    Gould Hall 830 Van Vleet Oval Rm. 105, Norman, OK, 73019, US
    35.205706 -97.445050
  • Bizzell Memorial LibraryBorrow it
    401 W. Brooks St., Norman, OK, 73019, US
    35.207487 -97.447906
  • Boorstin CollectionBorrow it
    401 W. Brooks St., Norman, OK, 73019, US
    35.207487 -97.447906
  • Chinese Literature Translation ArchiveBorrow it
    401 W. Brooks St., RM 414, Norman, OK, 73019, US
    35.207487 -97.447906
  • Engineering LibraryBorrow it
    Felgar Hall 865 Asp Avenue, Rm. 222, Norman, OK, 73019, US
    35.205706 -97.445050
  • Fine Arts LibraryBorrow it
    Catlett Music Center 500 West Boyd Street, Rm. 20, Norman, OK, 73019, US
    35.210371 -97.448244
  • Harry W. Bass Business History CollectionBorrow it
    401 W. Brooks St., Rm. 521NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • History of Science CollectionsBorrow it
    401 W. Brooks St., Rm. 521NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • John and Mary Nichols Rare Books and Special CollectionsBorrow it
    401 W. Brooks St., Rm. 509NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • Library Service CenterBorrow it
    2601 Technology Place, Norman, OK, 73019, US
    35.185561 -97.398361
  • Price College Digital LibraryBorrow it
    Adams Hall 102 307 West Brooks St., Norman, OK, 73019, US
    35.210371 -97.448244
  • Western History CollectionsBorrow it
    Monnet Hall 630 Parrington Oval, Rm. 300, Norman, OK, 73019, US
    35.209584 -97.445414
Processing Feedback ...